Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Company Deals

AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products

Fineline Cube Apr 17, 2026
Company Deals

Annoroad Gene Technology Files for Hong Kong IPO to Capitalize on Integrated Molecular Diagnostics Platform

Fineline Cube Apr 17, 2026
Company Deals

Mabwell Bioscience Expands Southeast Asia Reach with Malaysian Licensing Deal for Denosumab Biosimilars Rexeva and Denosu

Fineline Cube Apr 17, 2026
Company Deals Digital

Tigermed and Alibaba Cloud Forge Alliance to Build AI-Powered Ecosystem for Intelligent Clinical Trials

Fineline Cube Apr 17, 2026
Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Fineline Cube Apr 20, 2026
Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Fineline Cube Apr 20, 2026
Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Fineline Cube Apr 20, 2026
Company Policy / Regulatory

LEK Consulting’s Survey Reveals Biosecure Act’s Impact on Life Sciences Companies

Fineline Cube Jul 3, 2024

LEK Consulting, a UK/US firm, has published the results of a global survey aimed at...

Company Deals

Bristol-Myers Squibb Ends Collaboration with Eisai on Farletuzumab Eteribulin

Fineline Cube Jul 2, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY), a prominent US pharmaceutical company, has decided to terminate its...

Company Drug

Eli Lilly & Co. Strikes Deal for Radionetics’ GPCR-Targeted Radiopharmaceuticals

Fineline Cube Jul 2, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the US, has...

Company Drug

Boehringer Ingelheim Initiates Clinical Trial for Novel Anti-Obesity Drug

Fineline Cube Jul 2, 2024

Boehringer Ingelheim (BI), a German pharmaceutical company, has announced the commencement of clinical development for...

Company Drug

Tracon Pharmaceuticals Halts Development of Envafolimab After Clinical Trial Failure

Fineline Cube Jul 2, 2024

Tracon Pharmaceuticals (OTCMKTS: TCON), a US-based biopharmaceutical company, has decided to cease development of its...

Company Policy / Regulatory

US Forms ‘Bio-5’ Coalition with Global Powers to Reduce Reliance on Chinese APIs

Fineline Cube Jul 2, 2024

The White House announced last week a suite of new initiatives aimed at bolstering domestic...

Company Deals Medical Device

Cryofocus Medtech Partners with Boston Scientific for Respiratory Products Distribution in China

Fineline Cube Jul 2, 2024

Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced...

Company Deals

PW Medtech Group Ltd Plans Independent Listing of Rekind Medtec on NEEQ to Boost Growth

Fineline Cube Jul 2, 2024

PW Medtech Group Ltd (HKG: 1358), a prominent medical device manufacturer based in China, is...

Company Drug

Innovent Biologics Presents Positive Phase I Results for IBI343 at ESMO GI Congress 2024

Fineline Cube Jul 2, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Medical Device

Ningbo-Based Jenscare Scientific Announces Successful Follow-up Data for Transjugular Tricuspid Valve Device

Fineline Cube Jul 2, 2024

Jenscare Scientific Co., Ltd (HKG: 9877), a leading manufacturer of structural heart disease devices headquartered...

Company Drug

Yantai Dongcheng Pharmaceutical’s 177LuLNC1011 Gets FDA Green Light for Prostate Cancer Clinical Trial

Fineline Cube Jul 2, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...

Company Drug

SCG Cell Therapy Receives FDA Approval for HPV-Targeted SCG142 Clinical Trial

Fineline Cube Jul 2, 2024

SCG Cell Therapy Pte. Ltd, a Singapore-headquartered biotechnology company with a presence in Shanghai, has...

Company Drug

Boao Lecheng Approves Use of Sanofi’s Tzield as First-Line Therapy for Type 1 Diabetes Delay

Fineline Cube Jul 2, 2024

Tzield (teplizumab), recognized as the world’s first and only targeted therapy for delaying the onset...

Company Drug

Huadong Medicine’s ROR1-Targeting ADC HDM2005 Receives FDA Clinical Trial Approval

Fineline Cube Jul 2, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a pharmaceutical company based in China, has announced that...

Company Deals

Moon Biotech Secures Exclusive State-Owned Fund Investment in Series C+ Round

Fineline Cube Jul 2, 2024

Moon (Guangzhou) Biotech Co., Ltd, a leading microbiome platform company based in China, has reportedly...

Policy / Regulatory

China’s CDE Launches Pilot Program for Electronic Drug Registration Filings

Fineline Cube Jul 2, 2024

The National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) in China has issued...

Company Drug

China’s Sichuan Huiyu Pharmaceutical Halts Generic Cytosar Launch Following Strategy Review

Fineline Cube Jul 2, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a pharmaceutical company based in China, has announced...

Company Deals

China’s Henlius Biotech Partners with Sermonix for Japan Development of Breast Cancer Drug

Fineline Cube Jul 2, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a prominent biopharmaceutical company based in China, has announced...

Company Deals Medical Device

MicroPort Endovascular to Fully Acquire Optimum Medical Device in $65M Deal

Fineline Cube Jul 2, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading Chinese medical technology company, has...

Company Deals

Supercede Therapeutics Partners with Shanghai Universities for Anti-Tumor Cachexia Drug Developmen

Fineline Cube Jul 2, 2024

Fudan University and East China Normal University (ECNU) have entered into a global rights cooperation...

Posts pagination

1 … 324 325 326 … 653

Recent updates

  • China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores
  • Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026
  • Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026
  • Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio
  • AbbVie Partners with Santen China for Exclusive Distribution of Five Glaucoma Franchise Products
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NMPA Proposes New Quality Management Standards for Drug Retail Chains – Mandating Unified Systems Across Headquarters, Distribution Centers, and Stores

Company Drug

Xuanzhu Biopharmaceutical Reports Landmark Phase III DIAMOND-2 Results for Xuanfeining (Dirozalkib) in ALK-Positive NSCLC – 31.3-Month PFS Doubles Crizotinib Standard at AACR 2026

Company Drug

Sino Biopharmaceutical Reports 55% Response Rate for PD-1/VEGF Bispecific LM-299/MK-2010 in NSCLC at AACR 2026

Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.